Literature DB >> 10596717

Human herpes virus-8 associated primary effusion lymphoma of the pleural cavity in HIV-negative elderly men.

V Ascoli1, C C Scalzo, C Danese, K Vacca, A Pistilli, F Lo Coco.   

Abstract

Human herpes virus-8 (HHV-8)-associated primary effusion lymphoma (PEL) is an unusual lymphoma confined to the body cavities, which primarily affects human immunodeficiency virus (HIV)-positive men at high risk for Kaposi's sarcoma (KS). We describe two HIV-negative elderly Italian men, who developed pleural HHV-8-positive PEL in association with other diseases (systemic hypertension, colonic carcinoma, chronic obstructive airways disease, dilated cardiomyopathy), but without KS. Thoracic computed tomography revealed unilateral pleural effusion and pleural thickening. Thoracentesis disclosed large lymphoma cells, with no T- or B-cell associated antigens, clonal rearrangement of the immunoglobulin heavy chain gene and the presence of HHV-8 but not Epstein-Barr virus deoxyribonucleic acid sequences. Our cases differ from most pleural effusion lymphomas, in that they are non-acquired immunodeficiency syndrome-related. This highlights the possible human herpes virus-8-associated primary effusion lymphoma risk among elderly human immunodeficiency virus-negative patients, particularly Italians, in whom human herpes virus-8 seroprevalence rates and incidence of classic Kaposi's sarcoma are high.

Entities:  

Mesh:

Year:  1999        PMID: 10596717     DOI: 10.1183/09031936.99.14512319

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  9 in total

1.  Anti-CD20 monoclonal antibody treatment of human herpesvirus 8-associated, body cavity-based lymphoma with an unusual phenotype in a human immunodeficiency virus-negative patient.

Authors:  C L Pérez; S Rudoy
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

2.  An unusual case of posttransplant peritoneal primary effusion lymphoma with T-cell phenotype in a HIV-negative female, not associated with HHV-8.

Authors:  Ioannis Venizelos; Demetrio Tamiolakis; Maria Lambropoulou; Sylva Nikolaidou; Sophia Bolioti; Hlias Papadopoulos; Nikolas Papadopoulos
Journal:  Pathol Oncol Res       Date:  2005-09-29       Impact factor: 3.201

3.  Human Immunodeficiency Virus (HIV)-Negative and Human Herpes Virus-8 (HHV-8)-Positive Primary Effusion Lymphoma: A Case Report and Review of the Literature.

Authors:  Sonay Güven Karataş; Reyhan Bayrak; Ozlem Sahin Balçık; Kadir Serkan Yalçın; Esra Atıcı; Umit Akyıldız; Ali Koşar
Journal:  Turk J Haematol       Date:  2013-03-05       Impact factor: 1.831

4.  Primary effusion lymphoma involving three body cavities.

Authors:  Fadi Brimo; Gizelle Popradi; René P Michel; Manon Auger
Journal:  Cytojournal       Date:  2009-10-09       Impact factor: 2.091

5.  Imaging characteristics of pleural tumours.

Authors:  Luca De Paoli; Emilio Quaia; Gabriele Poillucci; Antonio Gennari; Maria Assunta Cova
Journal:  Insights Imaging       Date:  2015-10-16

Review 6.  Classic KSHV/HHV-8-positive Primary Effusion Lymphoma (PEL): A Systematic Review and Meta-Analysis of Case Reports.

Authors:  Ilaria Cozzi; Giovanni Rossi; Emma Rullo; Valeria Ascoli
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-03-01       Impact factor: 2.576

7.  Primary effusion lymphoma: an untrivial differential diagnosis for ascites.

Authors:  Funda Ceran; Yusuf Aydin; Levent Ozçakar; Unsal Han; Mehmet Yildiz
Journal:  Yonsei Med J       Date:  2009-12-18       Impact factor: 2.759

8.  An unusual case of Primary Effusion Lymphoma with aberrant T-cell phenotype in a HIV-negative, HBV-positive, cirrhotic patient, and review of the literature.

Authors:  Charitini Nepka; Dimitrios Kanakis; Maria Samara; Andreas Kapsoritakis; Spyridon Potamianos; Maria Karantana; Georgios Koukoulis
Journal:  Cytojournal       Date:  2012-06-29       Impact factor: 2.091

9.  Primary effusion lymphoma in human immune deficiency (HIV)-negative non-organ transplant immunocompetent patients.

Authors:  Lisi Yuan; James R Cook; Tarik M Elsheikh
Journal:  Diagn Cytopathol       Date:  2019-12-17       Impact factor: 1.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.